1. Disease Snapshot
- Highly aggressive neuroendocrine carcinoma of the lung
- Accounts for ~15% of lung cancers, almost exclusively in smokers
- Characterized by rapid doubling time and early metastasis
- Initial high chemo-sensitivity, but fast relapse is common
- Two-stage system (practical for treatment planning):
2. Treatment Overview SCLC is not typically managed surgically. The backbone is systemic chemotherapy ± radiotherapy ± immunotherapy, with platinum-based doublets as first-line.
A. Limited Stage (LS-SCLC) Goal: Cure, if possible
Standard approach:
- Cisplatin + Etoposide × 4 cycles + concurrent thoracic radiotherapy (early start, ideally with cycle 1 or 2)
- Carboplatin + Etoposide used if cisplatin not tolerated (renal, hearing, neuropathy issues)
Regimens:
- Cisplatin 75–80 mg/m² IV Day 1 + Etoposide 100 mg/m² IV Days 1–3, q21 days × 4 cycles
- Carboplatin AUC 5–6 Day 1 + Etoposide 100 mg/m² IV Days 1–3, q21 days × 4 cycles
Additional step:
- Prophylactic cranial irradiation (PCI) for patients with good response → reduces brain metastases risk
B. Extensive Stage (ES-SCLC) Goal: Prolong survival, improve quality of life
Standard since 2019: Platinum + Etoposide + PD-L1 inhibitor
- Atezolizumab regimen (IMpower133):
- Carboplatin AUC 5 Day 1 + Etoposide 100 mg/m² Days 1–3 + Atezolizumab 1200 mg Day 1 × 4 cycles → maintenance Atezolizumab
- Durvalumab regimen (CASPIAN):
- Cisplatin 75 mg/m² or Carboplatin AUC 5–6 Day 1 + Etoposide 80–100 mg/m² Days 1–3 + Durvalumab 1500 mg Day 1 × 4 cycles → maintenance Durvalumab
C. Relapsed Disease
- Platinum-sensitive relapse (>90 days from last platinum) → consider rechallenge with platinum doublet
- Platinum-refractory relapse (<90 days) → non-platinum options:
- Topotecan (oral or IV)
- Lurbinectedin
- Irinotecan
- Clinical trials
Toxicity Summary
| Agent/Class | Dose-Limiting Toxicity (DLT) | Other Common Toxicities | Pharmacist Monitoring & Prevention |
|---|---|---|---|
| Cisplatin | Nephrotoxicity | Ototoxicity, peripheral neuropathy, severe N/V, electrolyte wasting (Mg²⁺, K⁺, Ca²⁺), myelosuppression (mild) | Pre/post hydration (0.9% NaCl ± mannitol), antiemetic prophylaxis (NK1 + 5-HT3 + dexamethasone), baseline/periodic renal function, electrolytes, audiometry |
| Carboplatin | Myelosuppression (thrombocytopenia) | Anemia, neutropenia, N/V (mod–high), hypersensitivity (late cycles) | CBC before each cycle, dose via Calvert formula, renal function, infusion reaction precautions |
| Etoposide | Myelosuppression (neutropenia) | Alopecia, mucositis, hypotension (rapid infusion), secondary AML (rare) | CBC, infusion rate control (≥30–60 min), BP monitoring during infusion |
| Atezolizumab / Durvalumab (PD-L1 inhibitors) | Immune-mediated toxicities | Pneumonitis, hepatitis, colitis, thyroiditis, adrenal insufficiency, hypophysitis, rash | Baseline & periodic LFTs, TFTs, cortisol; patient education on cough, diarrhea, fatigue, rash; prompt corticosteroid initiation for grade ≥2 events |
| Thoracic Radiotherapy (LS-SCLC) | Esophagitis, pneumonitis | Fatigue, skin erythema, cough | Monitor swallowing, weight, hydration status, respiratory symptoms; coordinate supportive care with RT team |
| Prophylactic Cranial Irradiation (PCI) | Cognitive decline (late) | Fatigue, alopecia, headache, nausea | Baseline neurocognitive assessment, counsel on memory changes, manage fatigue, antiemetics for acute symptoms |
Synonyms
SCLC